STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STX-478’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Scorpion Therapeutics overview
Scorpion Therapeutics is a biotechnology company focusing on cancer biology, targeted oncology, and drug development. Scorpion Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of STX-478’s drug-specific PTSR and LoA scores, buy the report here.